ArticleThe oncologist2026
Impact of everolimus-related interstitial lung disease on subsequent treatment in patients with metastatic breast cancer.
Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEverolimus is an option for second-line or later use in combination with endocrine therapy for hormone receptor-positive breast cancer. An important everolimus-associated adverse event is drug-related interstitial lung disease (ILD), reported to occur in 16.0% of individuals in the BOLERO-2 trial, and 23.5% of those in the Asian subgroup. We aimed to examine the impact of everolimus-related ILD (e-rILD) on the risk of drug-related ILD during subsequent anti-cancer treatment. PATIENTS AND
methodsWe retrospectively studied the medical records of patients with metastatic breast cancer treated with everolimus plus endocrine therapy from January 2013 to March 2022, at the National Cancer Center Hospital East. We evaluated e-rILD grade using the Common Terminology Criteria for Adverse Events version 5.0.
resultsA total of 115 cases were treated with everolimus; 33 (28.7%) patients developed e-rILD of any grade, including 5 (15.2%) with grade ≥3 and 2 with grade 5. Management approaches for e-rILD included dose continuation, dose interruption, prednisolone 0.5-1.0 mg/kg, and steroid pulse. The proportions of patients who received subsequent treatment were similar between the e-rILD and no e-rILD groups (73.2% [60/82] vs 81.8% [27/33], respectively; P = .567). Subsequent therapies were generally similar between the 2 groups. Drug-related ILD during regimens following everolimus occurred in one patient (3.7%) with e-rILD and 2 patients (3.3%) without e-rILD (P = .930; odds ratio, 1.12; 95% CI, 0.10-12.86).
conclusione-rILD may not influence the choice of following treatment or the development of drug-related ILD during subsequent treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.